|
NUAK2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.43218770176645E-14 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.66322511319095E-12 |
| Normal-vs-Stage2 |
4.96869212440743E-12 |
| Normal-vs-Stage3 |
1.62947433324234E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
6.985400E-01 |
| Stage1-vs-Stage3 |
2.457200E-01 |
| Stage1-vs-Stage4 |
1.57058999999959E-05 |
| Stage2-vs-Stage3 |
2.758400E-01 |
| Stage2-vs-Stage4 |
9.140700E-03 |
| Stage3-vs-Stage4 |
1.082320E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.58761892521397E-14 |
| Normal-vs-AfricanAmerican |
3.4963032469193E-11 |
| Normal-vs-Asian |
1.62569957495862E-12 |
| Caucasian-vs-AfricanAmerican |
8.818200E-01 |
| Caucasian-vs-Asian |
1.002830E-01 |
| AfricanAmerican-vs-Asian |
3.547600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.44169137633799E-14 |
| Normal-vs-Female |
1.63680180520487E-12 |
| Male-vs-Female |
8.015000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62847513252018E-12 |
| Normal-vs-Age(41-60Yrs) |
1.64535052249448E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62525548574877E-12 |
| Normal-vs-Age(81-100Yrs) |
1.731610E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.467800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.659400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.224990E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.816200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.618810E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.015400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.722800E-03 |
| Classical-VS-Follicular |
9.560100E-02 |
| Classical-VS-Other |
9.982400E-01 |
| Classical-VS-Normal |
1.79856129989275E-14 |
| Tall-VS-Follicular |
1.257840E-03 |
| Tall-VS-Other |
4.738000E-01 |
| Tall-VS-Normal |
2.22044604925031E-16 |
| Follicular-VS-Other |
6.043400E-01 |
| Follicular-VS-Normal |
1.80244708047894E-12 |
| Other-VS-Normal |
3.419400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.6796564139554E-12 |
| Normal-vs-N1 |
2.22044604925031E-16 |
| N0-vs-N1 |
2.062800E-03 |
|
|
